Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1626 1654
This examiner grants 74% of resolved cases
Po-Chih Chen, an examiner in Tech Center 1600 and Art Unit 1621, has 771 resolved cases. The allowance rate is 74.2%, which is quite high. The median days to allowance is 883, showing a very efficient and fast prosecution process. This 883-day timeline is a significant advantage for applicants in Art Unit 1621. The 74.2% rate suggests a favorable environment for patent applicants.
The interview lift is 14.8%. This suggests that interviews provide a helpful boost to the 74.2% allowance rate. In Tech Center 1600, the 883-day median pendency is one of the faster timelines available. The 771 resolved cases provide a strong foundation for these metrics. The 14.8% lift indicates that direct communication can be used to resolve any remaining technical issues.
Applicants should be encouraged by the 74.2% allowance rate and the 883-day median to allowance. The 14.8% interview lift can be used to finalize allowable subject matter. In Art Unit 1621, this examiner's profile is favorable for practitioners. The 771 cases of experience suggest a predictable and efficient path to grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17568196 | COMPOSITION FOR PHOTOELECTRIC DEVICE, AND PHOTOELECTRIC DEVICE, IMAGE SENSOR, AND ELECTRONIC DEVICE INCLUDING THE SAME | Non-Final OA | Samsung Electronics Co., Ltd. |
| 16954098 | HETEROCYCLIC COMPOUND FOR USE IN ELECTRONIC DEVICES | Final Rejection | Merck Patent GmbH |
| 17788809 | 1,3-BUTYLENE GLYCOL PRODUCT | Final Rejection | DAICEL CORPORATION |
| 18292092 | Compound and Method for Preparing Same | Final Rejection | LG Energy Solution, Ltd. |
| 18575686 | METHODS OF TREATING OR PREVENTING CORONAVIRUS INFECTION WITH CANNABINOID ACIDS | Non-Final OA | Oregon State University |
| 18549281 | CRYSTALLINE FORMS OF (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUORO-METHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | Final Rejection | Bayer Aktiengesellschaft |
| 18846909 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PARKINSON'S DISEASE | Non-Final OA | Eisai R&D Management Co., Ltd. |
| 17220974 | SAFER, POTENT, AND FAST ACTING ANTIMICROBIAL AGENTS | Non-Final OA | Purdue Research Foundation |
| 17791684 | COMPLEXES OF N-HETEROCYCLIC CARBENES FOR TRANSITION METAL CATALYSIS | Final Rejection | Rutgers, The State University of New Jersey |
| 18832631 | COPOLYMER AND COSMETIC COMPOSITION CONTAINING SAID COPOLYMER | Non-Final OA | ADEKA CORPORATION |
| 18001516 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | Final Rejection | Icahn School of Medicine At Mount Sinai |
| 18290920 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | Non-Final OA | NURIX THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy